BRIDGEWATER, N.J.--(BUSINESS WIRE)--The new Neurotez method will allow for an elegant and rapid way to screen a large number of patient-derived samples and measure the degree of confidence in predicting a subject’s risk for getting Alzheimer’s disease, based on her/his TOMM40/APOE haplotype. TOMM40 has been implicated as a potential biomarker for those at risk for developing Alzheimer’s disease, based on work by Allen Roses’ team at Duke University’s Deane Drug Discovery Institute.
